2017 EHA Annual Meeting Highlights

Successful Reduction in Treatment Intensity in Patients with Advanced-stage Hodgkin Lymphoma Peter Borchmann, MD Begin

Estimating the Efficacy of Novel Therapies in Classical Hodgkin Lymphoma Paul Bröckelmann, MD Begin

Evaluating the Efficacy of Nivolumab with and without Brentuximab Vedotin: New Trial Results and Treating Rare Lymphoma Cases: Effective Strategies for NHLPH Andreas Engert, MD Begin

The Clinical Impact of PET-guided Treatment in Advanced-stage Hodgkin Lymphoma Andrea Gallamini, MD Begin

Overall Survival in Classical Hodgkin Lymphoma: Real-world Experiences in Kentucky Hayder Saeed, MD Begin

Early Trial Results of Combination Therapy with Brentuximab Vedotin in Hodgkin Lymphoma are Very Promising Anas Younes, MD Begin